BioSpace News Archive

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that preclinical data for TG-1701, the Company’s highly selective, BTK inhibitor, has been selected for presentation at the upcoming 2020 American Association for Cancer Research (AACR) annual meeting, to be held virtually The presentation details are as follows: Title : TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, does not inhibit anti-CD20-driven ADCC and ADCP in vitro, and

Pure Sunfarms achieves fifth consecutive profitable quarter and 179% quarter-to-quarter growth in retail branded product sales volume; builds on retail success in Ontario with 20% market share in April; continues leadership in low-cost cultivation VANCOUVER, British Columbia, May 15, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the first quarter of 2020 for its 41.3%-owned joint vent

Poster presentation will show updated pharmacodynamic and safety data of AST-008 from Exicure’s ongoing Phase 1b/2 study

exoVACC™ modular vaccine platform induces potent systemic and tissue resident T cell response - - Engineered exosomes allow for targeting of multiple cell types - CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced new preclinical data on programs using its proprietary engEx Platform. Highlights include new preclinical

Samsung Bioepis Announces Four-year Follow-up Data for Biosimilar ONTRUZANT ® (trastuzumab-dttb) in Early or Locally Advanced HER2-positive Breast Cancer Data to be presented at the ASCO20 Virtual Scientific Program Four-year event-free survival (EFS) and overall survival (OS) rates demonstrate biosimilarity between ONTRUZANT ® and reference trastuzumab INCHEON, Korea--( BUSINESS WIRE )-- Samsung Bioepis Co., Ltd. announced

IMV Inc. (the “Company” or “IMV”) (TSX:IMV; NASDAQ:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced financial results for the first quarter ended March 31, 2020 and provided an update on its clinical and operational progress.

Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904 New peptide-curcumin conjugate, TH1901, shows 100 times greater anti-cancer cell proliferation activity than unconjugated curcumin in vitro Results to be presented at American Association for Cancer Research (AACR) Virtual Annual Meeting II MONTREAL, May 15, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced five scientific posters sharing updated preclinical data at the American Association for Cancer Research (AACR) 2020 Annual Meeting, to be held virtually on June 22-24. The posters include preclinical data from Surface Oncology’s two lead clinical-stage antibody thera

Data support the initiation of an upcoming first-in-human trial for first-line, MRD+ multiple myeloma patients post-ASCT

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three months ended March 31, 2020 and provided a business update. “Despite the challenges caused by the emerging COVID-19 pandemic, we continued to make significant progress to advance the development of our lead compound,